A study was conducted to evaluate the inhibitory effects of vascular endothelial growth factor receptor 2 (VEGFR2) monoclonal antibody, BC001, against laser-induced choroidal neovascularization (CNV).
Methods:
We induced the experimental CNV in rhesus monkey eyes using laser photocoagulation. Monkeys were randomly assigned to 4 groups that received a single intravitreal administration of BC001 at 0 (vehicle-treated group), 0.05, 0.2, and 0.5 mg/eye. Fundus fluorescein angiography, optical coherence tomography, and histological studies were used for evaluations. The ocular recovery was determined by comparing changes of fluorescein leaking area and thickness of disrupted retina around the laser burn spot before and after drug administration. Choroidal blood vessels were stained and quantified by lectin staining. Hematoxylin and eosin staining was performed to determine the general histological complications.
Results:
An intravitreal injection of BC001 at 0.05, 0.2, and 0.5 mg per eye at 20 days after laser burn significantly reduced the CNV-induced fluorescein leakage, retina pathology, and aberrant choroidal vessel growth and did not change intraocular pressure or induce any immune response.
Conclusion:
BC001 confers significant inhibitory effects against laser-induced CNV in rhesus monkeys, thereby suggesting that prevention of VEGFR2 activation may be promising as an alternative therapeutic target for exudative age-related macular degeneration.
Get full access to this article
View all access options for this article.
References
1.
ZhangK., ZhangL., and WeinrebR.N.Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma. Nat. Rev. Drug Discov., 11:541–559, 2011.
2.
KleinR., PetoT., BirdA., and VannewkirkM.R.The epidemiology of age-related macular degeneration. Am. J. Ophthalmol., 137:486–495, 2004.
3.
ReinD.B., ZhangP., WirthK.E., et al.The economic burden of major adult visual disorders in the United States. Arch. Ophthalmol., 124:1754–1760, 2006.
4.
LiuY., WenF., HuangS., et al.Subtype lesions of neovascular age-related macular degeneration in Chinese patients. Graefes Arch. Clin. Exp. Ophthalmol., 245:1441–1445, 2007.
5.
ByeonS.H., LeeS.C., OhH.S., KimS.S., KohH.J., and KwonO.W.Incidence and clinical patterns of polypoidal choroidal vasculopathy in Korean patients. Jpn. J. Ophthalmol., 52:57–62, 2008.
6.
StratasB.A., WeipertJ.D., ReddickR.L., PerryD.D., and RiscoJ.M.Observations on the microvascular repair process after confluent argon laser photocoagulation. Arch. Ophthalmol., 104:126–129, 1986.
7.
MoisseievJ., AlhalelA., MasuriR., and TreisterG.The impact of the macular photocoagulation study results on the treatment of exudative age-related macular degeneration. Arch. Ophthalmol., 113:185–189, 1995.
8.
Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials—TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) study group. Arch. Ophthalmol., 117:1329–1345, 1999.
9.
ReichelE., BerrocalA.M., IpM., et al.Transpupillary thermotherapy of occult subfoveal choroidal neovascularization in patients with age-related macular degeneration. Ophthalmology., 106:1908–1914, 1999.
10.
FerraraN.Vascular endothelial growth factor and age-related macular degeneration: from basic science to therapy. Nat. Med., 16:1107–1111, 2010.
11.
AdamisA.P., MillerJ.W., BernalM.T., et al.Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am. J. Ophthalmol., 118:445–450, 1994.
12.
AielloL.P., AveryR.L., ArriggP.G., et al.Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N. Engl. J. Med., 331:1480–1487, 1994.
13.
ZhangF., TangZ., HouX., et al., VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis. Proc. Natl. Acad. Sci. U S A., 106:6152–6157, 2009.
14.
ZhongX., HuangH., ShenJ., et al., Vascular endothelial growth factor-B gene transfer exacerbates retinal and choroidal neovascularization and vasopermeability without promoting inflammation. Mol. Vis., 17:492–507, 2011.
15.
LiY., ZhangF., NagaiN., et al., VEGF-B inhibits apoptosis via VEGFR-1–mediated suppression of the expression of BH3-only protein genes in mice and rats. J. Clin. Invest., 118:913–923, 2008.
16.
Van de VeireS., StalmansI., HeindryckxF., et al.Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. Cell., 141:178–190, 2010.
17.
NgE.W., ShimaD.T., CaliasP., et al.Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat. Rev. Drug Discov., 5:123–132, 2006.
18.
RosenfeldP.J., BrownD.M., HeierJ.S., et al.Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med., 355:1419–1431, 2006.
19.
MartinD.F., MaguireM.G., YingG.S., GrunwaldJ.E., FineS.L., and JaffeG.J.Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N. Engl. J. Med., 364:1897–1908, 2011.
20.
RichR.M., RosenfeldP.J., PuliafitoC.A., et al.Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina., 26:495–511, 2006.
21.
NguyenQ.D., ShahS.M., HafizG., et al.A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. Ophthalmology. 113: 1522.e1–1522.e14., 2006.
22.
ZhangM., ZhangJ., YanM., LiH., YangC., and YuD.Recombinant anti-vascular endothelial growth factor fusion protein efficiently suppresses choridal neovasularization in monkeys. Mol. Vis., 14:37–49, 2008.
23.
ZhangM., ZhangJ., YanM., et al.A phase 1 study of KH902, a vascular endothelial growth factor receptor decoy, for exudative age-related macular degeneration. Ophthalmology., 118:672–678, 2011.
24.
ClarkeJ.M., and HurwitzH.I.Targeted inhibition of VEGF receptor 2: an update on ramucirumab. Expert. Opin. Biol. Ther., 13:1187–1196, 2013.
25.
KrzystolikM.G., AfshariM.A., AdamisA.P., et al.Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch. Ophthalmol., 120:338–346, 2002.
26.
ZahnG., VossmeyerD., StragiesR., et al., Preclinical evaluation of the novel small-molecule integrin alpha5beta1 inhibitor JSM6427 in monkey and rabbit models of choroidal neovascularization. Arch. Ophthalmol., 127:1329–1335, 2009.
27.
OnamiH., NagaiN., MachidaS., et al.Reduction of laser-induced choroidal neovascularization by intravitreal vasohibin-1 in monkey eyes. Retina., 32:1204–1213, 2012.
28.
FuchsC.S., TomasekJ., YongC.J., et al.Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet., 383:31–39, 2014.
29.
BarleonB., SozzaniS., ZhouD., WeichH.A., MantovaniA., and MarmeD.Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood., 87:3336–3343, 1996.
30.
GabrilovichD., IshidaT., OyamaT., et al.Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood., 92:4150–4166, 1998.
31.
OsadaT., ChongG., TansikR., et al.The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunol. Immunother., 57:1115–1124, 2008.
32.
LeppanenV.M., JeltschM., AnisimovA., et al.Structural determinants of vascular endothelial growth factor-D receptor binding and specificity. Blood., 117:1507–1515, 2011.
